Dr. Abraham is a member of the National Comprehensive Cancer Network (NCCN) Breast Cancer Committee, which sets treatment guidelines for breast cancer management across the United States. He is Vice Chair of the Research Strategy Committee of NRG Oncology, one of the largest cancer research groups in the world, funded by the National Cancer Institute. Dr. Abraham is also a member of the Breast Committee Working Group for NRG Oncology. He is the Vice Chair of the Research Review Committee for the National Surgical Adjuvant Breast and Bowel Project (NSABP) and a member of the Scientific Advisory Board for NSABP.
In 2013, Dr. Abraham joined Cleveland Clinic as director of the Breast Oncology Program, where he leads several national and local clinical trials to find better treatment options for early stage, metastatic, triple negative and her-2 positive breast cancer patients.
He is the national Principal Investigator of the NSABP FB-10 (Neratinib and TDM-1) clinical trial for her-2 positive metastatic breast cancer. He has more than 200 papers and presentations at national meetings.